MedTrace Logo

Serotonergic Pharmacotherapy for Agitation of Dementia

NCT00009204 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2017-06-16

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo-controlled, fixed dose study currently being conducted on two geropsychiatric units at Western Psychiatric Institute and Clinic. It seeks to evaluate the short-term safety and efficacy of citalopram and perphenazine in the treatment of 112 patients suffering from behavioral disturbances associated with dementia. Findings from this research may directly lead to improved acute pharmacotherapy for psychosis and behavioral problems in patients diagnosed with dementia. Improved treatment of behavioral complications with reduced side effects would reduce excess disability in patients diagnosed with dementia, allowing them to be maintained in the community for greater periods of time.

Conditions

  • Dementia
  • Alzheimer Disease
  • Dementia, Vascular

Interventions

DRUG

Citalopram [Celexa]

DRUG

Perphenazine [Trilafon]

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Bruce Pollock

    lead OTHER

Principal Investigators

  • Bruce G. Pollock, M.D., Ph.D. · Western Psychiatric Institute and Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-09-30
Primary Completion
2000-04-30
Completion
2002-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00009204 on ClinicalTrials.gov